Grifols SA
Company Profile
Business description
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Contact
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles
Barcelona08174
ESPT: +34 935710500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
23,822
Stocks News & Analysis
stocks
Unconventional wisdom: Are dividends the answers?
stocks
Netflix: A business that’s nearly flawless
stocks
Trump’s US dollar assault is fuelling CBA’s rise
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,934.30 | 45.10 | -0.50% |
CAC 40 | 7,834.58 | 16.30 | 0.21% |
DAX 40 | 24,217.50 | 78.43 | -0.32% |
Dow JONES (US) | 44,901.92 | 208.01 | 0.47% |
FTSE 100 | 9,120.31 | 18.06 | -0.20% |
HKSE | 25,388.35 | 278.83 | -1.09% |
NASDAQ | 21,108.32 | 50.36 | 0.24% |
Nikkei 225 | 41,456.23 | 370.11 | -0.88% |
NZX 50 Index | 12,853.46 | 48.33 | 0.38% |
S&P 500 | 6,388.64 | 25.29 | 0.40% |
S&P/ASX 200 | 8,666.90 | 42.50 | -0.49% |
SSE Composite Index | 3,593.66 | 12.07 | -0.33% |